BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GENFIT Corp. (ALGFT): Conversions Into Shares of 30 Bonds OCA2012-2


4/29/2013 10:03:30 AM

Lille (France), Boston (Massachusetts, United States), April 29th, 2013 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the conversions into shares of 30 bonds OCA2012-2 in keeping with the convertible loan contract signed with the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd.

In keeping with the 1st and 2nd resolutions of the Extraordinary Shareholders’ Meeting held on December 18th, 2012 and with the convertible loan contract signed with the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd (“the Bondholder”), the Bondholder requested one first conversion on April 25th, and then two other conversions on April 26th, 2013 for a total value of €300,000.

The first conversion on April 25th of 10 bonds OCA2012-2 into 17,714 new shares was performed at a conversion rate of €5.64, issue premium included, equivalent to 95% of the arithmetic mean of the volumeweighted average GENFIT share price for the five trading days (April 18th, 2013- April 24th, 2013) prior to the conversion request.

The two other conversions on April 26th of a total of 20 bonds OCA2012-2 into 35,270 new shares was performed at a conversion rate of €5.67, issue premium included, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five trading days (April 19th, 2013- April 25th, 2013) prior to the conversion requests.

As a result of these reserved share issues:

- The social capital of GENFIT has increased from €5,086,105.75 to €5,099,351.75;

- The number of shares representing the social capital of GENFIT has increased by 52,984, from 20,344,423 to 20,397,407 shares;

- The amount of the 7th installment of the bond loan agreement that remains to be converted is €600,000.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT’s research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT’s lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board

Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian

Ph. +33 1 7544 8740 / +336 8788 4726 – barabian@milestones.fr



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES